Skip to main content
SpringerLink
Log in

Cost savings with dust mite immunotherapy in Spain

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. This study was sponsored by Merck, SL

Reference

  • Garcia Robaina JC et al. Savings associated with high-dose hypoallergenic house dust mite immunotherapy in rhinitis and/or asthma patients in Spain. ClinicoEconomics and Outcomes Research : 14 Jun 2016. Available from: URL: https://dx.doi.org/10.2147/CEOR.S107123

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost savings with dust mite immunotherapy in Spain. PharmacoEcon Outcomes News 756, 16 (2016). https://doi.org/10.1007/s40274-016-3165-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3165-3

Search

Navigation